iAnthus Capital Holdings, Inc. operates licensed cannabis cultivation, processing, and dispensary facilities in the U.S. A key concern is its low liquidity, with a current ratio of 0.17, indicating potential difficulty in meeting short-term obligations. Additionally, the company has a negative net margin of -40.8%, raising questions about profitability. However, it boasts a gross margin of 45.5%, suggesting strong product pricing or cost management. The low stock price and market cap may reflect investor skepticism despite these strengths.
Loading financial metrics...
Company posted a loss of $-55.4M over the last year, representing 39.7% of revenue.
Debt of $239.1M is 29.7x the company's cash position of $8.0M.
Revenue decreased 10.7% year-over-year from $156.3M to $139.5M.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)